CST, 91473SF, IDO (D5J4E) Rabbit Monoclonal Antibody (BSA and Azide Free)

Monoclonal Antibody for studying IDO. Validated for WB,IHC,IHC,IF,F. Highly specific and rigorously validated in-house, IDO (D5J4E) Rabbit Monoclonal Antibody (BSA and Azide Free) (CST #91473) is ready to ship. Product Usage Information This product is the carrier free version of product #86630. All data were generated using the same antibody clone in the standard formulation which contains BSA and glycerol. This formulation is ideal for use with technologies requiring specialized or custom antibody labeling, including fluorophores, metals, lanthanides, and oligonucleotides. It is not recommended for ChIP, ChIP-seq, CUT&RUN, or CUT&Tag assays. If you require a carrier-free formulation for chromatin profiling, please contact us . Optimal dilutions/concentrations should be determined by the end user. BSA and Azide Free antibodies are quality control tested by size exclusion chromatography (SEC) to determine antibody integrity. Formulation Supplied in 1X PBS (10 mM Na 2 HPO 4 , 3 mM KCl, 2 mM KH 2 PO 4 , and 140 mM NaCl (pH 7.8)). BSA and Azide Free. For standard formulation of this product see product # 86630 . Storage Store at -20°C. This product will freeze at -20°C so it is recommended to aliquot into single-use vials to avoid multiple freeze/thaw cycles. A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance. Specificity / Sensitivity IDO (D5J4E) Rabbit Monoclonal Antibody (BSA and Azide Free) recognizes endogenous levels of total IDO (IDO-1, INDO) protein. This antibody does not cross-react with IDO-2 (INDOL1). Some nonspecific staining of normal breast epithelium has been observed. Species Reactivity: Human Source / Purification Monoclonal antibody is produced by immunizing animals with recombinant human IDO protein. Background INDO/IDO1/indoleamine 2,3-dioxygenase (IDO) is an IFN-γ-inducible enzyme that catalyzes the rate-limiting step of tryptophan degradation (1). IDO is upregulated in many tumors and in dendritic cells in tumor-draining lymph nodes. Elevated tryptophan catabolism in these cells leads to tryptophan starvation of T cells, limiting T cell proliferation and activation (2). Therefore, IDO is considered an immunosuppressive molecule, and research studies have shown that upregulation of IDO is a mechanism of cancer immune evasion (3). The gastrointestinal stromal tumor drug, imatinib, was found to act, in part, by reducing IDO expression, resulting in increased CD8 T cell activation and induction of apoptosis in regulatory T cells (4). In addition to its enzymatic activity, IDO was recently shown to have signaling capability through an immunoreceptor tyrosine-based inhibitory motif (ITIM) that is phosphorylated by Fyn in response to TGF-β. This leads to recruitment of SHP-1 and activation of the noncanonical NF-κB pathway (5). Alternate Names I23O1; IDO; IDO-1; IDO1; INDO; indolamine 2,3 dioxygenase; indole 2,3-dioxygenase; Indoleamine 2,3-dioxygenase 1; indoleamine-pyrrole 2,3 dioxygenase; Indoleamine-pyrrole 2,3-dioxygenase Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 43 Source/Isotype: Rabbit IgG